Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Espen Schallmayer

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|August 9, 2023
A Fluorescence-Based Reporter Gene Assay to Characterize Nuclear Receptor ModulatorsEspen Schallmayer, Daniel Merk
Archiv Der Pharmazie|March 19, 2024
Screening of Chelidonium majus isoquinoline alkaloids reveals berberine and chelidonine as selective ligands for the nuclear receptors RORβ and HNF4α, respectivelySohrab Salehi, Espen Schallmayer, Nils Bandomir, et al.
Communications Chemistry|February 3, 2025
Chemogenomics for steroid hormone receptors (NR3)Espen Schallmayer, Laura Isigkeit, Lewis Elson, et al.
Journal of Medicinal Chemistry|May 1, 2023
Development of a Potent Nurr1 Agonist Tool for In Vivo ApplicationsJan Vietor, Christian Gege, Tanja Stiller, et al.
Journal of Medicinal Chemistry|April 1, 2021
Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and PharmacokineticsSimone Schierle, Apirat Chaikuad, Felix F Lillich, et al.
Nature Communications|June 18, 2024
Chemogenomics for NR1 nuclear hormone receptorsLaura Isigkeit, Espen Schallmayer, Romy Busch, et al.
Journal of Medicinal Chemistry|May 8, 2025
A First-in-Class Hepatocyte Nuclear Factor 4 AgonistEspen Schallmayer, Vasily Morozov, Silke Duensing-Kropp, et al.
Nature Communications|September 11, 2024
Automated design of multi-target ligands by generative deep learningLaura Isigkeit, Tim Hörmann, Espen Schallmayer, et al.
ACS Chemical Biology|November 1, 2022
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective ModulatorsJan Heering, Nathalie Jores, Whitney Kilu, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Methods in Molecular Biology (Clifton, N.J.)|August 9, 2023
A Fluorescence-Based Reporter Gene Assay to Characterize Nuclear Receptor ModulatorsEspen Schallmayer, Daniel Merk
Archiv Der Pharmazie|March 19, 2024
Screening of Chelidonium majus isoquinoline alkaloids reveals berberine and chelidonine as selective ligands for the nuclear receptors RORβ and HNF4α, respectivelySohrab Salehi, Espen Schallmayer, Nils Bandomir, et al.
Communications Chemistry|February 3, 2025
Chemogenomics for steroid hormone receptors (NR3)Espen Schallmayer, Laura Isigkeit, Lewis Elson, et al.
Journal of Medicinal Chemistry|May 1, 2023
Development of a Potent Nurr1 Agonist Tool for In Vivo ApplicationsJan Vietor, Christian Gege, Tanja Stiller, et al.
Journal of Medicinal Chemistry|April 1, 2021
Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and PharmacokineticsSimone Schierle, Apirat Chaikuad, Felix F Lillich, et al.
Nature Communications|June 18, 2024
Chemogenomics for NR1 nuclear hormone receptorsLaura Isigkeit, Espen Schallmayer, Romy Busch, et al.
Journal of Medicinal Chemistry|May 8, 2025
A First-in-Class Hepatocyte Nuclear Factor 4 AgonistEspen Schallmayer, Vasily Morozov, Silke Duensing-Kropp, et al.
Nature Communications|September 11, 2024
Automated design of multi-target ligands by generative deep learningLaura Isigkeit, Tim Hörmann, Espen Schallmayer, et al.
ACS Chemical Biology|November 1, 2022
Mechanistic Impact of Different Ligand Scaffolds on FXR Modulation Suggests Avenues to Selective ModulatorsJan Heering, Nathalie Jores, Whitney Kilu, et al.
Pageof 1